Atea Pharmaceuticals (AVIR) Current Assets (2019 - 2026)

Atea Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $263.2 million for Q1 2026.

• On a quarterly basis, Current Assets fell 39.31% year-over-year to $263.2 million in Q1 2026; TTM through Mar 2026 was $263.2 million, a 39.31% decrease from a year earlier, with the FY2025 full-year figure at $311.0 million, down 32.74% from the prior year.
• Current Assets retreated to $263.2 million in Q1 2026 per AVIR's latest filing, from $311.0 million in the prior quarter.
• Across five years, Current Assets topped out at $713.2 million in Q1 2022 and bottomed at $263.2 million in Q1 2026.
• The 5-year median for Current Assets is $548.8 million (2024), against an average of $525.1 million.
• Across the five-year window, Current Assets slipped 9.95% in 2023 and tumbled 39.31% in 2026, its largest moves.
• Year by year, Current Assets stood at $660.9 million in 2022, then slipped by 10.66% to $590.5 million in 2023, then dropped by 21.7% to $462.4 million in 2024, then plunged by 32.74% to $311.0 million in 2025, then retreated by 15.37% to $263.2 million in 2026.
• Per Business Quant, the three latest AVIR Current Assets figures stand at $263.2 million (Q1 2026), $311.0 million (Q4 2025), and $336.1 million (Q3 2025).